AL8326

DRUG3 trials

Sponsors

Advenchen Pharmaceuticals LLC, Advenchen Pharmaceuticals, LLC.

Conditions

Breast NeoplasmsEndometrial NeoplasmsSmall Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.Soft Tissue Sarcoma (STS)

Phase 1

A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers

Not yet recruitingNCT07811232

Advenchen Pharmaceuticals, LLC.Endometrial Neoplasms, Soft Tissue Sarcoma (STS), Breast Neoplasms

Start: 2026-09-01End: 2031-09-01Target: 138Updated: 2026-09-10

Phase 2

A Phase 2 Evaluation of the Safety and Efficacy of AL8326 in ≥2nd Line Small Cell Lung Cancer (SCLC) Treatment

WithdrawnCTIS2023-509067-24-00

Advenchen Pharmaceuticals LLCSmall Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.

Target: 30Updated: 2024-06-21

A Phase 2 Evaluation of the Safety and Efficacy of AL8326 in ≥2nd Line Small Cell Lung Cancer (SCLC) Treatment

RecruitingCTIS2023-509067-24-01

Advenchen Pharmaceuticals LLCSmall Cell Lung Cancer (SCLC) patients who need ≥2nd line treatment without or with brain metastasis which is controlled with no active hemorrhage.

Start: 2025-06-17Target: 30Updated: 2025-07-30